20.500.12556/DiRROS-19027 Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas a single centre experience Background. Advanced follicular lymphoma (FL) and mantle cell lymphoma (MCL) are incurable diseases with conventional treatment. The high dose treatment (HDT) with autologous stem cell transplantation (ASCT), however, offers a certain proportion of these patients the prospect of a prolonged disease-free and overall survival. The aim of this study was to investigate the event free survival (EFS) and overall survival (OS) in patients with FL and MCL treated with ASCT. Patients and methods. Seventeen patients with FL and 29 patients with MCL were included, 15 of them were trans- planted to consolidate the response to second line treatment and 24 to consolidate their first remission, respectively. All were conditioned with total body irradiation (TBI) and high dose cyclophosphamide between 2006 and 2014 and all were transplanted with peripheral blood stem cells. Results. The estimated 5-year OS for FL was 87.8% (95% confidence interval [CI] 59.5%-96.8%) and for MCL 79.3% (95% CI 56.1%-91.1%), respectively. The estimated 5-year EFS for FL was 76.0% (95% CI 48.0%-90.3%) and for MCL 69.8% (95% CI 45.5%-84.8%), respectively. There were no secondary hematological malignancies observed in either group. Conclusions. Based on above results, the ASCT with TBI is a good treatment option in terms of long-term survival for patients with follicular and mantle cell lymphoma demonstrating a relatively low rate of late toxicities and secondary malignancies. follicular lymphoma mantle cell lymphoma autologous stem cell transplantation folikularni limfom limfom plaščnih celic avtologna presaditev matičnih celic true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-06-03 09:13:35 2024-06-03 09:13:35 2024-06-04 03:38:29 0000-00-00 00:00:00 2017 0 0 Soavtorji: Karlo Pintaric, Jože Pretnar, Maja Pohar Perme, Barbara Jezersek Novakovic; str. 81-87, VIII no. 1 Vol. 51 Mar. 2017 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2017-03-01 616-006 1318-2099 10.1515/raon-2016-0040 32754393 https://www.degruyter.com/view/j/raon.ahead-of-print/raon-2016-0040/raon-2016-0040.xml 1 cb947766-2178-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26111 RAZ_Boltezar_Lucka_2017.pdf RAZ_Boltezar_Lucka_2017.pdf 1 41E9FB07A98A0E27387C86DA6F7DF53A 6cf4f06fd5e9802b70f0f9a9f297811023aeb3d7f81af11699b40b2b54dde4ae f724acfb-2178-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26112 Onkološki inštitut Ljubljana 0 0 0